Valuation: HeartSciences Inc.

Market Cap 20.28M 17.68M 16.7M 15.16M 28.41M 1.95B 28.52M 200M 77.18M 989M 76.17M 74.48M 3.18B P/E 2027 *
-1.81x
P/E 2028 * -2.59x
Enterprise Value 20.28M 17.68M 16.7M 15.16M 28.41M 1.95B 28.52M 200M 77.18M 989M 76.17M 74.48M 3.18B EV / Sales 2027 *
1,186x
EV / Sales 2028 * 6.44x
Free-Float
75.29%
Yield 2027 *
-
Yield 2028 * -
1 day+7.44%
1 week+53.39%
Current month+65.08%
1 month+144.13%
3 months+182.61%
6 months+101.55%
Current year+68.28%
1 week 3.25
Extreme 3.25
5.21
1 month 2.37
Extreme 2.37
5.21
Current year 1.63
Extreme 1.63
5.21
1 year 1.63
Extreme 1.63
5.21
3 years 1.63
Extreme 1.63
52
5 years 1.63
Extreme 1.63
600
10 years 1.63
Extreme 1.63
600
Manager TitleAgeSince
Chief Executive Officer 57 2022-02-28
Director of Finance/CFO 44 2022-03-31
Chief Tech/Sci/R&D Officer - 2014-06-30
Director TitleAgeSince
Chairman 57 2013-05-31
Director/Board Member 54 2013-12-31
Director/Board Member 70 2020-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Free

Chief Financial Officer

25,000 0.7598%
1/12/26 Free

Director

15,000 0.4720%
1/12/26 Free

Director

15,000 0.4720%
Change 5-day change 1-year change 3-year change Capi.($)
+7.44%+53.39%+47.73%-92.51% 18.87M
-2.17%-1.88%-38.02%+17.40% 3.68B
+0.33%+6.91%-3.06% - 1.45B
-2.52%+3.13%+94.03% - 959M
-4.00%-23.91% - - 275M
+1.17%+1.96%-13.33%+4.00% 147M
+5.68%+6.59%+64.91%+43.28% 111M
Average +0.85%+5.77%+25.38%-6.96% 949.26M
Weighted average by Cap. -1.52%+0.50%-7.56%+17.10%

Financials

2027 *2028 *
Net sales 17.1K 14.91K 14.08K 12.79K 23.95K 1.64M 24.05K 169K 65.08K 834K 64.24K 62.81K 2.68M 3.15M 2.75M 2.59M 2.36M 4.41M 302M 4.43M 31.07M 11.99M 154M 11.83M 11.57M 494M
Net income -12.32M -10.74M -10.14M -9.21M -17.26M -1.18B -17.33M -122M -46.89M -601M -46.28M -45.25M -1.93B -10.6M -9.24M -8.72M -7.92M -14.84M -1.02B -14.9M -104M -40.32M -517M -39.8M -38.92M -1.66B
Net Debt - -
Logo HeartSciences Inc.
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Employees
14
Date Price Change Volume
26-09-18 US$5.200 +7.44% 174,529
26-09-17 US$4.840 +27.70% 388,299
26-09-16 US$3.790 +10.17% 91,717
26-09-15 US$3.440 -2.82% 65,665
26-09-14 US$3.540 +4.42% 81,060
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.200USD
Average target price
10.00USD
Spread / Average Target
+92.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HSCS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!